Exonics Therapeutics

Merck R&D chief Roger Perlmutter offers some heavyweight R&D glam to a little upstart biotech out to cure Duchenne MD
Endpoints
Tue, 01/30/18 - 09:26 am
Merck
R&D
Roger Perlmutter
Duchenne Muscular Dystrophy
Exonics Therapeutics
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up
Xconomy
Wed, 11/8/17 - 09:24 am
Exonics Therapeutics
Duchenne Muscular Dystrophy
CRISPR
gene therapy
A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD
Endpoints
Mon, 02/27/17 - 09:13 am
Duchenne Muscular Dystrophy
R&D
CRISPR-Cas9
Exonics Therapeutics